Danaher Corporation

Danaher reported second-quarter 2026 sales of $6.3 billion, core revenue growth of 3% year over year, and core growth of 4.5% excluding respiratory testing revenue. Gross profit margin was 57.6%, adjusted operating margin was 27.1%, and adjusted diluted EPS was $1.94, up approximately 8% year over year. Free cash flow was $1.3 billion in the quarter and $2.4 billion in the first half, with year-to-date free cash flow to net income conversion of 124%. For Q3, management expects revenue growth of approximately 2%-3%, with about a 250 basis point respiratory testing headwind, and adjusted operating profit margin of about 26.5%. For full-year 2026, Danaher expects core revenue growth of 3%-4% and adjusted diluted EPS of $8.45-$8.60, versus the prior $8.35-$8.55 range.

Rainer Blair said the quarter reflected better-than-expected revenue, earnings, and cash flow, helped by stronger commercial execution, recent innovation, and improving end markets. He emphasized that core growth accelerated sequentially, life sciences had its strongest quarter in several years, diagnostics performed well, and underlying bioprocessing orders remained robust even with shipment timing delays. His tone was constructive and confident, repeatedly pointing to a balanced portfolio, strong secular growth drivers, and the Danaher Business System as long-term differentiators.

Matt Gugino highlighted the financial bridge behind the raised outlook: the company absorbed mix and FX headwinds, but benefited from a better Q2 and the earlier-than-expected Masimo close. He said the EPS increase to $8.45-$8.60 includes roughly $0.07-$0.08 from the early Masimo close, and described the midpoint as implying nearly 10% EPS growth. On bioprocessing, he quantified the timing shift as a bit over $100 million moved from Q2/Q3 into next year, while noting Q2 was hurt by about a 500-basis point impact to bioprocessing growth and that the company is not assuming a Q4 catch-up in its plan.

Analysts focused heavily on bioprocessing shipment delays, asking whether the issue signaled a broader visibility problem or a multi-quarter rebase. Management said the pushouts were concentrated in a few large commercial customers and primarily involved resin shipments tied to site readiness and production schedule changes, not a broad demand deterioration; they also pointed to mid-teens order growth in both consumables and equipment. Questions also centered on the second-half growth cadence, the life sciences recovery, and the early Masimo contribution, with management saying diagnostics should reaccelerate as respiratory headwinds fade, life sciences is benefiting from better biotech funding and stronger commercial execution, and Masimo is off to a high-single-digit growth start.